Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations

Heidi Erlandsen, Angel L. Pey, Alejandra Gámez, Belén Pérez, Lourdes R. Desviat, Cristina Aguado, Richard Koch, Sankar Surendran, Stephen Tyring, Reuben Matalon, Charles R. Scriver, Magdalena Ugarte, Aurora Martínez, Raymond C. Stevens

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH 4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.

Original languageEnglish (US)
Pages (from-to)16903-16908
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number48
DOIs
StatePublished - Nov 30 2004

Fingerprint

Phenylalanine Hydroxylase
Phenylketonurias
Mutation
Enzymes
Phenylalanine
Oral Administration
Catalytic Domain
Peptide Hydrolases
sapropterin

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. / Erlandsen, Heidi; Pey, Angel L.; Gámez, Alejandra; Pérez, Belén; Desviat, Lourdes R.; Aguado, Cristina; Koch, Richard; Surendran, Sankar; Tyring, Stephen; Matalon, Reuben; Scriver, Charles R.; Ugarte, Magdalena; Martínez, Aurora; Stevens, Raymond C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 48, 30.11.2004, p. 16903-16908.

Research output: Contribution to journalArticle

Erlandsen, H, Pey, AL, Gámez, A, Pérez, B, Desviat, LR, Aguado, C, Koch, R, Surendran, S, Tyring, S, Matalon, R, Scriver, CR, Ugarte, M, Martínez, A & Stevens, RC 2004, 'Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 48, pp. 16903-16908. https://doi.org/10.1073/pnas.0407256101
Erlandsen, Heidi ; Pey, Angel L. ; Gámez, Alejandra ; Pérez, Belén ; Desviat, Lourdes R. ; Aguado, Cristina ; Koch, Richard ; Surendran, Sankar ; Tyring, Stephen ; Matalon, Reuben ; Scriver, Charles R. ; Ugarte, Magdalena ; Martínez, Aurora ; Stevens, Raymond C. / Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 48. pp. 16903-16908.
@article{c02d6d682b614b77915973f5c41aebb5,
title = "Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations",
abstract = "Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30{\%} of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH 4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.",
author = "Heidi Erlandsen and Pey, {Angel L.} and Alejandra G{\'a}mez and Bel{\'e}n P{\'e}rez and Desviat, {Lourdes R.} and Cristina Aguado and Richard Koch and Sankar Surendran and Stephen Tyring and Reuben Matalon and Scriver, {Charles R.} and Magdalena Ugarte and Aurora Mart{\'i}nez and Stevens, {Raymond C.}",
year = "2004",
month = "11",
day = "30",
doi = "10.1073/pnas.0407256101",
language = "English (US)",
volume = "101",
pages = "16903--16908",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations

AU - Erlandsen, Heidi

AU - Pey, Angel L.

AU - Gámez, Alejandra

AU - Pérez, Belén

AU - Desviat, Lourdes R.

AU - Aguado, Cristina

AU - Koch, Richard

AU - Surendran, Sankar

AU - Tyring, Stephen

AU - Matalon, Reuben

AU - Scriver, Charles R.

AU - Ugarte, Magdalena

AU - Martínez, Aurora

AU - Stevens, Raymond C.

PY - 2004/11/30

Y1 - 2004/11/30

N2 - Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH 4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.

AB - Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH 4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.

UR - http://www.scopus.com/inward/record.url?scp=10044279157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044279157&partnerID=8YFLogxK

U2 - 10.1073/pnas.0407256101

DO - 10.1073/pnas.0407256101

M3 - Article

VL - 101

SP - 16903

EP - 16908

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -